President Trump’s Executive Order on Prescription Drug Prices

Following President Trump’s announcement on a new executive order aimed at reducing prescription drug prices in the U.S., the focus has shifted to the current costs and potential savings for Americans. The order emphasizes aligning American drug prices with those in “the most preferred countries,” meaning patients will pay the lowest prices found in other developed nations.

Trump noted some prices for certain prescription medications could drop significantly—by as much as 50% to 90%.

Katy Dubinsky, a pharmacist in New York and the CEO of Vitalize, welcomed the initiative, highlighting that it addresses long-standing issues in the healthcare system. However, she cautioned about the challenges of implementation, mentioning that the drafting of regulations could take several months before any actual cost reductions are realized.

Expensive Prescription Drugs in the U.S.

Dubinsky provided insight into some of the costliest prescription drugs available in the country today:

• 1. Atidarsagene autotemcel by Orchard Therapeutics – $4.25 million

This medication treats metachromatic leukodystrophy (MLD), a rare genetic disorder affecting the nervous system. It’s a one-time treatment intended to halt the disease’s progression in young children.

• 2. Hemgenix by CSL Behring – $3.5 million

This treatment is designed for hemophilia B, helping the body produce its own coagulation factors, thus eliminating the need for ongoing injections.

• 3. Elevidys by Sarepta Therapeutics – $3.2 million

This drug addresses Duchenne muscular dystrophy (DMD) and aims to slow the condition’s progression in boys.

• 4. Skysona by BluebirdBio – $3 million

Utilized for cerebral adrenoleukodystrophy (CALD), this therapy seeks to mitigate brain damage in affected boys.

• 5. Zynteglo by BluebirdBio – $2.8 million

This gene therapy helps individuals with beta thalassemia produce healthy red blood cells, reducing the need for regular transfusions.

Dubinsky stated that significant price drops for many prescription drugs are anticipated, although the effects of the executive order may take time to materialize.

Drugs and Sales Volume

John Stanford, who leads Incubate, discussed the expensive drugs in terms of sales volume rather than their high per-patient costs. He emphasized that government efforts often prioritize drugs with larger market impacts, rather than those used for rare conditions with smaller patient bases.

• 1. Keytruda by Merck – $25 billion

This immunotherapy treats various cancers and is a key part of Merck’s portfolio.

• 2. Eliquis by Bristol-Myers Squibb and Pfizer – $189.5 billion

A well-established prescription for preventing blood clots.

• 3. Ozempic by Novo Nordisk – $139.3 billion

Originally for type 2 diabetes, this drug has gained popularity for its weight loss effects.

• 4. Humira by AbbVie – $14.4 billion

This longstanding treatment for inflammatory conditions has generated massive revenue over the years.

• 5. Biktarvy by Gilead – $11.85 billion

Biktarvy serves as a major HIV treatment and a financial foundation for Gilead’s research into other areas.

Impacts of the Executive Order

Dr. Jacob Glanville pointed out that many generic drugs and vaccines won’t be significantly impacted by the new executive order, as their prices tend to be considerably lower. He remarked on the unsustainable nature of U.S. healthcare costs and the expenses associated with some treatments, which can range dramatically.

Some therapies, especially those in innovative fields like gene therapy and personalized medicine, can carry staggering price tags, sometimes reaching up to $500,000 for a complete treatment plan.

Experts believe that while lowering drug prices is essential, it shouldn’t hinder future innovations. If costs for essential new treatments remain high, adapting the landscape for drug production and clinical trials may be necessary to maintain progress in medical advancements.